参考文献/References:
[1] BECKETT M W,ARDERN C I,ROTONDI M A. A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer’s disease in older adults[J]. BMC geriatrics,2015,15(1):109-116.
[2]王国佐,龚盛强,尹芳等. 脑血管疾病与阿尔茨海默病的联系及其机制[J]. 世界中医药,2016,11(9):1897-1900.
[3]JIAN L,YANG C,GANG R,et al. Screening hepatotoxic components in Euodia rutaecarpa by UHPLC-QTOF/MS based on the spectrum-toxicity relationship[J]. Molecules,2017,22(8):1264-1278.
[4]STRATMANN K,HEINSEN H,KORF H W,et al. Precortical phase of Alzheimer’s disease(AD)-related tau cytoskeletal pathology[J]. Brain pathology,2016,26(3):371-386.
[5]韩兆丰,刘士敏,刘晓倩,等. 吴茱萸碱对AD模型小鼠的保护作用及学习记忆能力的调节作用[J]. 现代中药研究与实践,2018,165(6):28-30.
[6]YUAN S M,GAO K,WANG D M,et al. Evodiamine improves congnitive abilities in SAMP8 and APPswe/PS1ΔE9 transgenic mouse models of Alzheimer’s disease[J]. Acta pharmacologica sinica,2011,32(3):295-302.
[7]王冬梅,马元武,袁树民,等. 柚皮苷及其与吴茱萸碱联合用药对APP～(swe)/PS～(ΔE9)转基因痴呆模型小鼠学习记忆能力的影响[J]. 中国实验动物学报,2012,20(2):59-63.
[8]WANG D,WANG C,LIU L,et al. Protective effects of evodiamine in experimental paradigm of Alzheimer’s disease[J]. Cognitive neurodynamics,2018,12(3):303-313.
[9]ZHANG Y F,WANG J Q,WANG C Y,et al. Pharmacological basis for the use of evodiamine in Alzheimer’s disease:antioxidation and antiapoptosis[J]. International journal of molecular sciences,2018,19(5):1527-1541.
[10]SHIN K Y,KIM K Y,SUH Y H. Dehydroevodiamine. HCl enhances cognitive function in memory-impaired rat models[J]. Korean journal of physiol pharmacol,2017,21(1):55-64.
[11]SHIN K Y,NOH S J,PARK C H,et al. Dehydroevodiamine. HCl protects against memory impairment and cerebral amyloid-β production in Tg2576 mice by acting as a β-secretase inhibitor[J]. CNS & neurological disorders drug targets,2016,15(8):935-944.
[12]LIU X,ZHOU J,ABID M D N,et al. Berberine attenuates axonal transport impairment and axonopathy induced by calyculin A in N2a cells[J]. Plos one,2016,11(3):e0152609.
[13]FANG J,LIU R,TIAN Q,et al. Dehydroevodiamine attenuates calyculin A-induced tau hyperphos-phorylation in rat brain slices[J]. Acta pharmacologica sinica,2010,28(11):1717-1723.
[14]PENG J H,ZHANG C E,WEI W,et al. Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats[J]. Neuropharmacology,2007,52(7):1521-1527.
[15]孙文蕾. 吴茱萸碱对阿尔茨海默病模型大鼠HMGB1/TLR4/NF-κB信号通路的研究[D]. 石家庄:河北医科大学,2015.
[16]ZHAO T,ZHANG X,ZHAO Y,et al. Pretreatment by evodiamine is neuroprotective in cerebral ischemia:up-regulated pAkt,pGSK3β,down-regulated NF-κB expression,and ameliorated BBB permeability[J]. Neurochemical research,2014,39(8):1612-1620.
[17]LIU A J,WANG S H,HOU S Y,et al. Evodiamine induces transient receptor potential vanilloid-1-mediated protective autophagy in U87-MG astrocytes[J]. Evidence-based complementray and alternative medicine,2013(2):354840.
[18]任妮娜,杨奕樱,潘春等. 吴茱萸碱对动脉粥样硬化大鼠抗炎抗氧化作用的研究[J]. 贵阳中医学院学报,2018,40(2):21-26.
[19]WEI J,CHING L C,ZHAO J F,et al. Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis[J]. Acta physiologica,2013,207(2):299-307.
[20]SANTOS,CLáUDIA Y,SNYDER P J,et al. Pathophysiologic relationship between Alzheimer’s disease,cerebrovascular disease,and cardiovascular risk:a review and synthesis[J]. Alzheimer’s & dementia:diagnosis,assessment & disease monitoring,2017,7:69-87.